Arena Pharmaceuticals to Present at Citigroup's Global Healthcare Conference
SAN DIEGO, May 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at
Citigroup's Global Healthcare Conference on May 24, 2007 at 11:00 a.m. Eastern
Time (8:00 a.m. Pacific Time) at the Hilton New York Hotel in New York City.
Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific
Officer, is scheduled to provide a corporate overview of the company and its
clinical development and discovery programs.
A live audio webcast of the presentation will be available under the
investor relations section of Arena's website at www.arenapharm.com. A replay
of the presentation will be available for 30 days following the event. Please
connect to Arena's website several minutes prior to the start of the webcast
to ensure adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing oral drugs in four major
therapeutic areas: cardiovascular, central nervous system, inflammatory, and
metabolic diseases. Arena's most advanced product candidate, lorcaserin, is
being investigated in a Phase 3 clinical trial program for the treatment of
obesity. Arena's broad pipeline of novel compounds targeting G
protein-coupled receptors, an important class of validated drug targets,
includes compounds being evaluated independently and with its partners, Merck
& Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals® and Arena® are registered service marks of the
company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, preclinical and internal
and partnered clinical programs, and ability to develop compounds and
commercialize drugs. For such statements, Arena claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or results may
differ materially from Arena's expectations. Factors that could cause actual
results to differ materially from the forward-looking statements include, but
are not limited to, Arena's planned clinical trials may not proceed at the
time Arena expects or at all, the results of preclinical studies or clinical
trials may not be predictive of future results, Arena's ability to partner
lorcaserin, APD125, APD791 or other of its compounds or programs, the timing,
success and cost of Arena's research, out-licensing endeavors and clinical
trials, Arena's ability to obtain additional financing, Arena's ability to
obtain and defend its patents, and the timing and receipt of payments and
fees, if any, from Arena's collaborators. Additional factors that could cause
actual results to differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking statements
represent Arena's judgment as of the time of this release. Arena disclaims any
intent or obligation to update these forward-looking statements, other than as
may be required under applicable law.
SOURCE Arena Pharmaceuticals, Inc.
Jack Lief, President and CEO, or David Walsey, Director, Corporate Communications,
both of Arena Pharmaceuticals, Inc., +1-858-453-7200, ext. 1682; or Media Relations,
E. Blair Schoeb of WeissComm Partners, +1-760-365-1857, for Arena Pharmaceuticals,